Effect of Neoadjuvant Chemoradiotherapy on Locally Advanced Rectal Mucinous Adenocarcinoma: A Propensity Score-Matched Study
Table 1
Patient characteristics in unmatched and propensity-matched rectal mucinous adenocarcinomas.
Characteristics
Unmatched patients
Propensity-matched patients
nCRT ()
Surgery alone ()
P value
nCRT ()
Surgery alone ()
P value
Gender
0.094
0.682
Male
39 (63.9)
52 (50.5)
27 (56.2)
25 (52.1)
Female
22 (36.1)
51 (49.5)
21 (43.8)
23 (47.9)
Age (years)
0.918
0.540
ASA score
0.418
0.787
1
33 (54.1)
52 (50.5)
24 (50.0)
26 (54.2)
2
21 (34.4)
44 (34.4)
18 (37.5)
18 (37.5)
3
7 (11.5)
7 (6.8)
6 (12.5)
4 (8.3)
BMI (kg/m2)
0.122
0.626
Distance from the anal verge (cm)
0.005
0.455
Tumor diameter (cm)
<0.001
0.461
Gross type
0.156
0.565
Expanding
27 (26.2)
13 (21.3)
12 (25.0)
12 (25.0)
Ulcering
72 (69.9)
41 (67.2)
30 (62.5)
33 (68.8)
Infiltrating
4 (3.9)
7 (11.5)
6 (12.5)
3 (6.2)
Clinical T stage
0.047
0.637
T3
15 (24.6)
41 (39.8)
13 (27.1)
11 (22.9)
T4
46 (75.4)
60.2 (60.2)
25 (72.9)
37 (77.1)
Clinical N stage
0.782
0.695
N0
8 (13.1)
12 (11.7)
4 (8.3)
3 (6.2)
N+
53 (86.9)
91 (88.3)
44 (91.7)
45 (93.8)
Pretreatment CEA level
0.256
0.404
Normal (<5 ng/mL)
33 (54.1)
65 (63.1)
27 (56.2)
31 (64.6)
Elevated (≥5 ng/mL)
28 (45.9)
38 (36.9)
21 (43.8)
17 (35.4)
nCRT: neoadjuvant chemoradiotherapy; ASA: American Society of Anesthesiologists; BMI: body mass index. Data are expressed as (%) or as median ± standard deviation, where appropriate. Row percents are presented. Significant differences are in bold.
